Literature DB >> 11409790

A review and evaluation of research on the deaf-blind from perceptual, communicative, social and rehabilitative perspectives.

J Rönnberg1, E Borg.   

Abstract

This paper reviews research on deaf-blind individuals, primarily from behavioral and communicative points of view. Inclusion in the population of deaf-blind is qualified by describing a variety of subgroups and genetically based syndromes associated with deaf-blindness. Sensory assessment procedures--based primarily on residual capacities--are appraised. Consequences for everyday life are described briefly. Non-sensory, alternative classificatory schemes and procedures are presented and the results from behavior modification procedures used for correcting maladaptive behaviors are summarized. Methods for communicating tactilely are described and evaluated. Attention is also drawn to some suggestions regarding learning of alphabetic codes and sign acquisition. Finally, suggestions for future research are proposed.

Entities:  

Mesh:

Year:  2001        PMID: 11409790     DOI: 10.1080/010503901300112176

Source DB:  PubMed          Journal:  Scand Audiol        ISSN: 0105-0397


  4 in total

1.  Symptoms of autism among children with congenital deafblindness.

Authors:  Jesper Dammeyer
Journal:  J Autism Dev Disord       Date:  2014-05

2.  Children with Usher syndrome: mental and behavioral disorders.

Authors:  Jesper Dammeyer
Journal:  Behav Brain Funct       Date:  2012-03-27       Impact factor: 3.759

3.  Neuroplasticity associated with tactile language communication in a deaf-blind subject.

Authors:  Souzana Obretenova; Mark A Halko; Ela B Plow; Alvaro Pascual-Leone; Lotfi B Merabet
Journal:  Front Hum Neurosci       Date:  2010-01-04       Impact factor: 3.169

Review 4.  Participation experiences of people with deafblindness or dual sensory loss: A scoping review of global deafblind literature.

Authors:  Atul Jaiswal; Heather Aldersey; Walter Wittich; Mansha Mirza; Marcia Finlayson
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.